Objective: To determine the frequency of medication use in patients with dystonia enrolled in an international biorepository study.
Methods:In a cross-sectional analysis, we included 2,026 participants enrolled at 37 sites in the United States, Canada, Europe, and Australia through Project 1 of the Dystonia Coalition, an international biorepository study. The primary aim was to assess the frequency of medication classes recommended for treating patients with dystonia, and the secondary aim was to compare characteristics (disease type, age, sex, duration of disease, comorbid conditions, severity).Results: Querying the database for the presence of any medication for dystonia used (includes both injectable and oral therapy), we found 73% using medications (n 5 1,488) and 27% using no dystonia medications (n 5 538). Furthermore, 61% of the total sample used botulinum toxin (BoNT) therapy alone or in combination. Differences were found in medication use patterns by dystonia type, with the lowest oral medication use in focal dystonia and highest use in generalized dystonia; by region, with highest BoNT therapy rate reported in Italy and the lowest in the Northeast region of the United States; and by focal dystonia subtype, with highest BoNT therapy alone in blepharospasm and spasmodic dysphonia (49%) and lowest in other cranial dystonia (32%).
Conclusions:The majority of patients with dystonia enrolled in the Dystonia Coalition Project 1 were using medications to treat their dystonia. Overall, a complex picture of medication use patterns emerged, with factors such as region, disease duration, type of dystonia, disease severity, and psychiatric comorbidities all playing a significant role. Neurology ® 2017;88:543-550
GLOSSARYBoNT 5 botulinum toxin; DBS 5 deep brain stimulation; GDRS 5 Global Dystonia Rating Scale.Although botulinum toxin (BoNT) injections are the gold standard therapy for patients with focal dystonia, oral medications such as anticholinergics and GABAergic classes are typically recommended in published treatment reviews on dystonia.1 We currently do not know the range or type of oral medications actually used in patients with dystonia (alone or combined with BoNT).In a study performed as an online survey, most patients (86%) with a self-reported diagnosis of cervical dystonia had used BoNT, and the majority of patients (53%) also reported oral medication for their dystonia symptoms.2 This study supports that many patients with dystonia use oral medications, but we do not know the type or class of medication used in this population.We conducted a cross-sectional study in an international cohort to better characterize and understand medication use in the dystonia population. This study provides an opportunity to explore the potential therapeutic gap in the treatment of dystonia and whether this gap might differ among the subtypes of dystonia, requiring a precision medicine approach.